Open Interest and Volume Dynamics
The latest data reveals Lupin’s open interest rising sharply by 8,081 contracts, a 16.88% increase from the previous figure of 47,878 to 55,959. This substantial uptick in OI is accompanied by a futures volume of 19,484 contracts, underscoring robust trading activity in the derivatives market. The combined futures and options value stands at approximately ₹18,583.6 lakhs, with futures contributing ₹16,404.1 lakhs and options an overwhelming ₹17,956.4 crores, indicating significant capital flow and investor interest.
Underlying the derivatives activity, Lupin’s spot price closed at ₹2,268, marking a 1.58% gain on the day. This outperformance is notable against the Pharmaceuticals & Biotechnology sector’s decline of 0.49% and the Sensex’s broader fall of 0.90%, highlighting Lupin’s relative strength in a challenging market environment.
Market Positioning and Investor Behaviour
The surge in open interest alongside rising volume suggests fresh directional bets are being placed by market participants. Typically, an increase in OI coupled with rising prices signals new long positions entering the market, reflecting bullish sentiment. Conversely, if OI rises while prices fall, it may indicate fresh short positions. In Lupin’s case, the price appreciation alongside OI growth points towards accumulation and positive market positioning.
Further supporting this view is the delivery volume on 11 May, which surged to 17.1 lakh shares, an 82.25% increase over the five-day average delivery volume. This rise in delivery volume indicates stronger investor participation in the cash market, reinforcing the conviction behind the derivatives activity. The stock’s liquidity, sufficient to support trade sizes of up to ₹12.21 crores based on 2% of the five-day average traded value, facilitates such active positioning without undue price impact.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Technical and Trend Analysis
Lupin’s price action reveals a nuanced technical picture. The stock has reversed its recent two-day decline, gaining 0.71% on the day, outperforming both its sector and the Sensex. It trades above its 100-day and 200-day moving averages, signalling a longer-term uptrend, though it remains below the shorter-term 5-day, 20-day, and 50-day averages. This suggests some near-term consolidation or profit-taking, but the overall trend remains constructive.
The combination of rising open interest, increased delivery volumes, and price recovery after a brief dip points to strengthening investor confidence. The mid-cap pharmaceutical firm’s market cap stands at ₹1,03,061 crores, reflecting its significant presence in the sector and capacity to attract institutional interest.
Mojo Score and Analyst Ratings
MarketsMOJO assigns Lupin a robust Mojo Score of 84.0, upgrading its grade from Buy to Strong Buy as of 4 May 2026. This upgrade reflects improved fundamentals, technical momentum, and valuation metrics. The strong buy rating aligns with the recent surge in derivatives activity and positive price action, suggesting that analysts see further upside potential in the stock.
Such a rating upgrade often influences investor sentiment, encouraging fresh inflows and reinforcing the bullish positioning observed in the derivatives market. Lupin’s standing in the Pharmaceuticals & Biotechnology sector, combined with its mid-cap status, makes it an attractive candidate for both growth and value-oriented portfolios.
Want to dive deeper on Lupin Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Implications for Investors and Market Outlook
The pronounced increase in open interest and volume in Lupin’s derivatives signals a clear shift in market positioning towards a more bullish stance. Investors appear to be anticipating positive developments, possibly linked to the company’s strong fundamentals, sectoral tailwinds, or upcoming catalysts. The stock’s ability to outperform its sector and the broader market on a day of general weakness further underscores its relative strength.
However, the technical indicators suggest some caution in the short term, as the stock remains below its shorter-term moving averages. This could imply a period of consolidation before a sustained upward move. Investors should monitor open interest trends closely, as a continued rise alongside price appreciation would confirm the bullish momentum, while any divergence might signal profit-booking or a change in sentiment.
Given Lupin’s mid-cap status and liquidity profile, it remains accessible for institutional and retail investors alike, making it a key stock to watch within the Pharmaceuticals & Biotechnology sector. The recent upgrade to a Strong Buy by MarketsMOJO adds further conviction to the positive outlook.
Conclusion
Lupin Ltd.’s recent surge in open interest and volume in the derivatives market, coupled with its price recovery and strong analyst upgrade, paints a compelling picture of renewed investor confidence. The stock’s outperformance relative to its sector and the Sensex amidst broader market weakness highlights its resilience and potential for further gains. While short-term technical resistance remains, the overall trend and market positioning suggest Lupin is well poised for continued momentum in the coming weeks.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
